WebMs. Collins has more than 40 years of leadership experience in cell and gene therapies … WebJan 22, 2024 · CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Katrine Bosley has decided to step down from her ...
Editas Medicine Appoints Cynthia Collins President & CEO
WebApr 13, 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1. WebJul 26, 2024 · Ms. Collins most recently served as the CEO of Editas Medicine, and prior to that served as the CEO of Human Longevity, Inc.; the CEO/GM of the Cell Therapy and Lab Business of General... golf courses southern new hampshire
Who We Are Editas Medicine
WebFeb 10, 2024 · Cynthia Collins owns about 43,760 units of Editas Medicine, Inc … WebJan 23, 2024 · In the meantime, Cynthia Collins, a member of the company’s board, will assume the role of interim CEO. Bosley will remain with Editas in an advisory role through the end of the year in order to ensure a smooth transition, the company said. Neither Editas nor Bosley provided a reason in the announcement for her decision to leave the company. WebAug 13, 2024 · Editas Medicine CAMBRIDGE, Mass. (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed Cynthia (Cindy) Collins, a 30-plus year industry veteran currently serving as the Company’s interim CEO as President and Chief … healogics awards